The Department of Health and Human Services (HHS) has announced that the monoclonal antibody therapy bamlanivimab and antibody cocktail casirivimab/imdevimab will no longer be allocated to health departments, and that authorized health care providers should order directly from AmerisourceBergen Corporation (ABC), the drugs’ sole distributor. The products remain free of charge to requesting sites.
This content is restricted to members.
